Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834403 | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 37 | The Methodist Hospital Research InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03831711 | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 5 | Andrei IagaruOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02636582 | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2023 | clinicaltrials |
| NCT01142401 | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | completed | Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT03358017 | Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer(YAPPETIZER) | completed | Phase 2 | 54 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 3 | Oct 17, 2023 | clinicaltrials |
| NCT03121352 | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04032080 | LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Dawn L. HershmanOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT02637024 | Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation(OPAR) | completed | Phase 2 | 280 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 12 | Joyce O'ShaughnessyOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03018080 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer(PePPy) | completed | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03454529 | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | completed | Phase 2 | 24 | Michael SimonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02673398 | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | completed | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT02768701 | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT00921115 | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | completed | Phase 2 | 42 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT02526498 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery(TRIUMPH-T) | completed | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01417286 | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 69 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01922921 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | completed | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT02314156 | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | completed | Phase 2 | 67 | Northwestern UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02401347 | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | completed | Phase 2 | 21 | Melinda TelliOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04320030 | [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers(EITHICS) | completed | Phase 2 | 13 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03735966 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. | completed | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT03057600 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | completed | Phase 2 | 52 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT03167619 | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)(DORA) | completed | Phase 2 | 45 | Duke UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03154749 | DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer | completed | Phase 2 | 93 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03394027 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02282345 | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | completed | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT02536794 | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT01904903 | Cardiac Safety Study in Patients With HER2 + Breast Cancer(SAFE-HEaRt) | completed | Phase 2 | 31 | Medstar Health Research InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02698891 | Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | completed | Phase 2 | 127 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03243838 | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer(LANCET) | completed | Phase 2 | 31 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02297412 | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel | completed | Phase 2 | 47 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT02296801 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer(PALLET) | completed | Phase 2 | 307 | NSABP Foundation IncNETWORK | 3 | Jan 13, 2022 | clinicaltrials |
| NCT01849250 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2021 | clinicaltrials |
| NCT03931928 | Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients(TAMENDOX) | completed | Phase 2 | 356 | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)OTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2023source: clinicaltrials